Polyethylene glycol (PEG) is a cell membrane fusogen (de StGroth et al., 1980; Hoehn et al., 1978 [2]; Pontecorvo et al., 1975 [3]). In clinical application PEG allows some axonal fusion in peripheral nerve repairs, resulting in retention of some mobility and sensation during the regeneration process and reducing muscular atrophy. Several manuscripts exist concerning in vivo models of PEG fusion, while there is a distinct lack of in vitro studies. This study optimizes an experimental in vitro PEG fusion procedure in B35 rat neuroblastoma cells, through alteration of PEG and dimethyl sulfoxide (DMSO) concentrations and utilizes flow cytometry for assessment. The optimized procedure was then tested on B104-1-1 cells, a mouse neuroblastoma line expressing P2X7R, to validate our in vitro procedure/model against previous in vivo testing of P2X7R modulators, Brilliant Blue FCF (FCF) and bzATP. In brief, two cell populations were differentially stained, mixed, pre-treated (if applicable) and PEG-fused. Initial optimization generated the highest fusion rates with 70% PEG + 0% DMSO. Subsequent testing of the model with FCF and bzATP proved that assessment over time is required when evaluating potential modulators of PEG fusion. Our conclusion, at 72 h post PEG fusion, is that the optimized procedure is suitable for initial candidate testing of modulators of PEG fusion. In vitro experiments with FCF and bzATP corroborated previous in vivo findings and confirmed that DMSO is not required to aid PEG fusion in the in vitro model. The development of this cellular based in vitro model will be invaluable as a substitute for initial assessment of chemical modulators of PEG fusion.
Introduction
Peripheral nerve injury is common in the civilian population and among military personnel. However, despite advancing repair techniques, complete restoration of function is rare following injury and repair [4] . Beginning within days, the distal stumps of transected axons seal off and are degraded, requiring extensive periods of time to regenerate axons and innervate target muscles [5, 6] .
Polyethylene glycol (PEG) is a highly hydrophilic compound which has long been used in cellular hybridoma creation [1] [2] [3] . It has been theorized that the mechanism of PEG mediated fusion is a result of rapidly removing the water from plasma membranes, allowing lipids of closely apposed membranes to dissociate and fuse [7] . A wide range of sizes and concentrations of PEG have been studied displaying varying levels of cellular fusion [1, [8] [9] [10] [11] . One finding of note is the determination that PEG fusion occurs immediately and limiting exposure is essential to long-term survival of target cells [9, 11, 12] . The conditions of each study including cell types, adhered or suspended, PEG purity, and residual medium volume, affect a range of fusion results. Some reports indicate success with 1000 MW PEG, while others indicate 4000 MW was best [1, 9, 11] . PEG fusion is now being explored as a repair technique for peripheral nerve injuries, as it has been shown to rapidly restore continuity in severed peripheral nerves [13] [14] [15] [16] . In these experiments the antioxidant methylene blue was employed before application of PEG. Methylene blue is thought to decrease endogenous plasma membrane sealing post-injury and therefore could have implications for PEG-fusion [7] .
PEG has been studied in vivo using animal models and is currently undergoing trial in human patients [14, 17] . However, despite advances, in vitro models of the peripheral nervous system remain elusive. Some success has been seen through the use of dorsal root ganglion (DRG) explants in 3D models [18] , however these are technically challenging. Previous in vitro work from our group indicates a positive correlation between PEG concentration and fusion in a cellular model [19] . Herein we detail the further optimization of a simple in vitro PEG cell-fusion procedure/model featuring B35 rat neuroblastoma cells. B35 cells are neuronal in origin and easy to culture [20] . The purpose was to create an inexpensive, relatively quick, and reliable replacement to initial in vivo animal testing.
Following the initial optimization phase, the procedure/model was tested against previous findings from our group [21] demonstrating the effects of Brilliant Blue FCF (FCF) and 2 0 (3 0 )-O-(4-Ben zoylbenzoyl) adenosine 5 0 -triphosphate (bzATP) on PEG cellfusion. FCF and bzATP act upon the P2X7 receptor [22, 23] , an ionotropic ATP-gated receptor which induces the formation of pannexin pores upon activation [24] . This activation has important implications for fusion of severed axons, as it is implicated in organismal inflammatory response [25] and flooding of damaged axons with calcium, aiding in Wallerian degeneration initiation [23] . Brilliant Blue FCF (FCF) inhibits the P2X7 receptor while bzATP activates it [26] . B104-1-1 cells, a mouse neuroblastoma cell line, were selected for this set of experiments due to their neuronal nature and phenotypic exhibition of the P2X7 receptor [27] , which is not present in B35 cells.
Materials and methods

Cell culture
During initial optimization, B35 cells (American Type Culture Collection (ATCC); Manasses, VA) were plated and maintained in complete medium (DMEM/FBS: Dulbecco's modification of Eagle's medium; Mediatech; Manassas, VA/10% fetal bovine serum; Life Technologies; Carlsbad, CA), at 37°C with 5% CO 2 . Cells were harvested, with 0.025% trypsin (Mediatech; Manassas, VA) weekly for experimentation, and a subculture was generated for the following week's experiments. For the subsequent testing, B104-1-1 mouse neuroblastoma cells (ATCC) were cultured under identical conditions.
Cell harvesting and quantification
All cells were harvested by trypsin (Mediatech; Manassas, VA) dissociation and pelleted by centrifugation. All centrifugation steps were executed at 1000 rpm for 5 min. The pellet was resuspended in complete media and cells were quantified. Cells were diluted to 1 Â 10 6 cells/mL and 2 Â 10 6 cells were used for each assay. Triplicate samples were used during every experiment. To account for procedure/cell manipulation impact, a 0% PEG control was included. Controls underwent all procedures but received diluent only for fusion. To account for PEG cell-fusion alone, a 70% PEG only control was employed. An aliquot of unstained cells was retained for flow cytometry instrumentation preparation. For experiments with propidium iodide (PI, viability stain), two separate unstained aliquots were retained. 
Cell labeling
PEG cell-fusion
PEG solutions (w/v) were made from PEG 3350 kDa (SigmaAldrich; St. Louis, MO) in complete medium and the appropriate amount of DMSO (Sigma-Aldrich) for the trial-specific concentrations (w/v). PEG solutions were prepared, aliquoted and stored at 4°C ahead of time. Prior to each procedure, aliquots of PEG/DMSO were warmed to 37°C. Following cell labeling and mixing, cells were divided into 1 mL aliquots ($2 Â 10 6 cells/experimental sample) and pelleted. Triplicate samples were treated with 200 mL of PEG/DMSO for 1 min, during which time they were vortexed, at max speed, 3Â for 1 s each. After the 1-minute incubation period, 1 mL complete medium was added to each sample and each was vortexed 1Â for 1 s. Cells were pelleted, washed with 1 mL complete medium, pelleted again, washed with 1 mL D-PBS, and pelleted a final time before resuspension in 1 mL D-PBS for analysis by flow cytometry. A summary of PEG cell-fusion optimization experiments is shown in Table 1 .
Treatment with FCF and bzATP and temporal analysis
For experiments with B104-1-1 cells, FCF (Sigma-Aldrich) and bzATP (Sigma-Aldrich) solutions were prepared in D-PBS from stock solutions. Immediately prior to treatment with PEG, cells were pelleted and treated with 50 mL of FCF (10 mM, 30 mM, or 60 mM) or bzATP (5 mM, 10 mM, or 20 mM) solution. Samples were incubated for 1 min with manually agitation by hand vortexing. Following incubation, 1 mL of D-PBS was added to each sample and inverted 3x to mix. Cells were then pelleted, and PEG cellfusion was performed as previously described.
Immediately following PEG application, during the complete media wash, samples were resuspended, and 200 mL of each, including controls, was transferred into six-well tissue culture dishes (Fisher Scientific), supplemented with 4 mL complete media, and incubated at 37°C with 5% CO2 for 72 h. Remaining cells were pelleted and then washed with 500 mL D-PBS. Finally, all experimental samples and one aliquot of unstained cells were resuspended in 500 mL of D-PBS containing 0.5 mg/ml PI. The remaining aliquot of unstained cells, and the green-only and violet-only controls, was resuspended in 500 mL of D-PBS only. Table 2 shows a summary of B104-1-1 PEG cell-fusion experiments.
Following the 72 h incubation period, cells were harvested from the six-well plates, pelleted, and washed with 1 mL of complete medium. The unstained sample was resuspended, a small aliquot was used for quantification, and the remaining volume was divided into 2 samples. Cells from all samples were pelleted, washed in 500 mL of D-PBS, re-pelleted and then all experimental samples and one unstained control were resuspended in 250 mL of D-PBS containing 0.5 mg/ml PI. The other unstained control, as well as the green-only and violet-only controls, were resuspended in D-PBS only.
Flow cytometry
Flow cytometry experiments were performed in the VUMC Flow Cytometry Shared Resource Core. Samples were analyzed using the BD Fortessa analytical cytometer. CellTracker Green TM dye was excited with the BD GFP (Ex-Max 494 nm/Em-Max 520 nm) laser and CellTrace Violet TM was excited with the BD Pacific Blue (ExMax 401 nm/Em-Max 452 nm) laser. Cells were initially gated via forward scatter and side scatter, isolating viable, single cell events, and cellular fusion was quantified as the percentage of doublepositive cellular events within this gated population. Cell viability in initial B35 experiments was determined as the percent of total events represented in the gated population. In the later B104-1-1 experiments, cell viability was determined by PI labelling, and viability and fusion were analyzed as both percentages of the gated population and of the entire sample.
Results
B35 experiments/optimization of experimental procedure
Optimization was defined as maximizing cellular fusion while minimizing cellular death. To eliminate assay-to-assay variation, a set number of cells, 2 million/assay, was established and used consistently for each experiment. Average fusion rates for 0%, 50%, and 75% PEG of 0.5% (±0.00%), 1.1% (±0.45%), and 1.33% (±0.12%), respectively, were observed, confirming a trend for increased fusion with higher concentration of PEG. However, cellular viability was catastrophically low for 75% PEG (22.8% ± 12.51%).
PEG concentration range was narrowed, and fusion was investigated with 0%, 55%, 60% and 65% PEG, all with 5% DMSO. Data showed respective average fusion rates of 1.90% (±0.42%), 2.33% (±0.15%), 6.27% (±1.72%), and 6.30% (±0.85%), with cell viabilities of 75.47% (±1.19%), 74.37% (±0.85%), 59.70% (±15.36%), and 59.30% (±8.58%). These data indicate no difference between 60 and 65% PEG treatments in either fusion or viability. Based on previous data suggesting that higher PEG concentrations decrease cell viability, 60% PEG was chosen for the next phase of optimization.
DMSO concentrations of 5%, 3%, and 1%, all with 60% PEG, were tested against a 0% PEG + 5% DMSO control. There was no difference in fusion rates between 60% PEG + 3% DMSO (3.03% ± 0.50%) and 60% PEG + 1% DMSO (3.13% ± 0.15%), with both exhibiting increased fusion over 60% PEG + 5% DMSO (1.87% ± 0.32). There proved to be no differences in viability between any of the groups, prompting a reassessment of higher percentages of PEG with lower percentages of DMSO.
PEG solutions at 65% and 70% were reconsidered. Three iterations were performed (n = 9 for all groups) with 65% PEG and 70% PEG at both 1 and 0% DMSO, and 0% PEG at 1% DMS0 as a control (Fig. 1) . On average, the control group demonstrated 2.13% fusion (±0.28%) and 79.16% viability (±1.24%). 65% PEG with 1% and 0% DMSO demonstrated 4.12% fusion (±0.61%) and 2.83% fusion (±0.60%), with 77.72% viability (±1.34%) and 78.80% viability (±1.13%), respectively. 70% PEG with 1% and 0% DMSO demonstrated 4.71% fusion (±0.66%) and 5.28% fusion (±0.77%), with 77.18% viability (±1.46%) and 76.98% viability (±0.87%), respectively. While all the treatments demonstrated similar viability, data suggest that 65% PEG requires some DMSO to maximize fusion, while fusion with 70% PEG was unaffected by DMSO inclusion. Indeed 70% PEG + 0% DMSO expressed significantly higher rates of fusion than 65% PEG + 0% DMSO (p = 0.012) and was established as the desired concentration of PEG for future in vitro fusion experiments.
B104-1-1 experiments/application of procedure for chemical testing
This optimized in vitro experimental procedure was used to investigate the effects of FCF and bzATP on PEG cell-fusion. This investigation was a test of the experimental procedure, as previous in vivo PEG axonal-fusion studies have been performed with these substances [21] . A range of FCF (10-60 lM) and bzATP (5-20 lM) treatments were tested (n = 6) based on previously reported concentration used in vitro [28, 29] .
During our initial assessment, we noticed wide variation between the treatments, with bzATP generally showing higher fusions and lower viabilities immediately post-PEG cell-fusion. However, when we examined the 72 h samples, we were surprised to see that all samples receiving PEG decreased in fusion and increased in viability from baseline (Fig. 2) . Rodriguez-Feo et al. reported that by post-surgery day 3 there was little difference between FCF and bzATP treated nerve ligations. Upon a more thorough examination, a wide field of cell death was noted when examining the whole sample flow cytometry results (Fig. 3, circled  in red) . Our previous gating strategy eliminated these from our final number. The data were re-evaluated looking at the whole sample and there was a general decrease in both fusion and viability (Fig. 4) . Immediately following treatment and PEG cell-fusion, fusion for 60 mM FCF (1.60 ± 0.40; n = 6) was significantly lower than for 70% PEG alone (3.04 ± 0.43; n = 12) (p = 0.014) and all experimental samples had fusion rates significantly higher than 0% PEG control (0.20 ± 0.04; n = 12) (p < 0.05). No other differences in fusion rates were observed immediately post-treatment. Viability for 60 mM FCF (85.15 ± 2.02; n = 6) was significantly higher than 70% PEG alone (79.22 ± 2.51; n = 12) (p = 0.042), while no difference in viability was noted between 70% PEG alone and 10 mM FCF (83.62 ± 1.37; n = 6) or 30 mM FCF (82.57 ± 2.31; n = 6). When compared to viability of 0% PEG control (86.76 ± 0.71; n = 12), neither 30 mM FCF nor 60 mM FCF showed any difference, while 10 mM FCF showed a significant decrease (p = 0.038). No difference in viability was noted for any bzATP treated group compared to 70% PEG alone. The viability of 5 mM bzATP did not differ significantly from that of the 0% PEG control, while the viabilities of 10 mM bzATP and 20 mM bzATP were significantly lower (p = 0.029 and p = 0.023, respectively). Fusion rate for 60 mM FCF after 72 h (0.63 ± 0.03; n = 3) was significantly lower than 70% PEG alone (1.20 ± 0.21; n = 6) (p = 0.023). No difference was observed between fusion rates for 70% PEG alone after 72 h and 30 mM FCF (0.80 ± 0.06; n = 3). For bzATP samples, no difference was observed between fusion rates for 70% PEG alone after 72 h and 5 mM bzATP (1.70 ± 0.17; n = 3) or 20 mM bzATP (1.30 ± 0.10; n = 3). All samples demonstrated fusion rates significantly higher than 0% PEG control after 72 h (0.17 ± 0.02; n = 3). All PEG treated samples demonstrated a marked decrease in total fusion over time. Viabilities for both 30 mM FCF (81.33 ± 0.75; n = 6) and 60 mM FCF (82.40 ± 1.16; n = 5) were significantly higher than that of 70% PEG alone (79.50 ± 0.56; n = 11) (p = 0.038 and p = 0.033, respectively), while viability for 10 mM FCF (81.30 ± 1.15; n = 4) showed no difference from 70% PEG alone. No FCF sample differed in viability at 72 h from 0% PEG control (82.53 ± 0.62; n = 12). Viability for 20 mM bzATP after 72 h (69.07 ± 4.06; n = 6) was significantly lower than both 70% PEG alone and the 0% PEG control (p = 0.026 and p = 0.011, respectively). Both 5 mM bzATP (79.52 ± 1.55; n = 6) and 10 mM bzATP (77.40 ± 3.19; n = 5) showed no difference in viability compared to both 70% PEG alone and 0% PEG control at 72 h. The viabilities for 70% PEG alone and 0% PEG control remained significantly different at 72 h (p = 0.0008).
Discussion
Flow cytometry was our selected method to quantify cellular fusion, based on its ability to differentiate particles by both fluorescence and particle size, and its use as a technique to quantify fusion in similar studies [19, 30] . The PEG cell-fusion optimization generally showed an increase in fusion and a decrease in viability with increasing concentrations of PEG, correlating with our previous report [19] . Experiments 1-3 (Table 1) used DMSO at 5%, as it has been reported to increase PEG cell-fusion [31] . DMSO has been used extensively for a broad range of biological applications, including as a cryoprotectant, a cell membrane permeability enhancer, and in drug delivery [32] [33] [34] . However, it was hypothesized that DMSO may decrease cell viability but could be optimized to improve viability with minimal effect on fusion.
When optimizations were performed, there was a decrease in fusion observed for 65% PEG + 0% DMSO as compared to 65% PEG + 1% DMSO, while no similar trend was observed for the same DMSO variations with 70% PEG, suggesting the existence of a threshold PEG concentration above which DMSO inclusion is not necessary to improve fusion. Cheng et al. demonstrated the dehydrating effect of DMSO at the lipid membrane surface [35] , specifically that DMSO at low concentrations cause water molecules bound to the lipid headgroup to be replaced by DMSO. This observation was previously noted by He et al. in 2012, when during their (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
course of study they found that peak DMSO density at the interface occurred at low concentrations [36] . He et al. also noted that at low concentrations, DMSO needs time to condense onto the bilayer surface [36] . PEG being highly hydrophilic, and only requiring a brief exposure time for cell-cell fusions [9, 11, 12] , our observation could be explained by the slight increase in PEG removing and sequestering most of the water from the cell membrane, before any DMSO effects can be observed. Additionally, low concentrations of DMSO have been implicated in the influx of Ca 2+ , leading to vesicle formation to ''seal" leaky membranes [36] and increased plasmalemmal sealing following axotomies [37] . As the experimental purpose is to test substances which may enhance cell-cell fusion, any additive that may initiate sealing prior to cell-cell fusion occurring would preferentially be avoided. Treatment with 70% PEG without DMSO increased PEG cell-fusion significantly over 65% PEG without DMSO. We tested our in vitro model against previously reported in vivo comparison of p2x7R effectors to determine its efficacy for future experimentation. Rodriguez-Feo et al. (2013) observed improved recovery and axonal regeneration at three weeks in rats treated with PEG + FCF as compared to PEG + bzATP. This finding was attributed to PEG-mediated increases in axonal fusion in FCFtreated nerves due to inhibition of the P2X7 receptor, while bzATP treatment reduced fusion through receptor activation. In our experiment, bzATP had minimal effect on fusion, with no bzATP treatment altering fusion rates compared to 70% PEG alone. However, it was catastrophic for cell viability, indicating that activation of the P2X7 receptor persists for an extended period to the detriment of the cell. The inclusion of 0% PEG and 70% PEG controls were essential in assessing these temporal effects. The in vitro procedure requires several centrifugation, vortexing and mixing steps, which are taxing on the cells. In Fig. 3 , there appears to be a high number of dead cells, even in the 0% PEG control sample, and in fact, the average whole sample cell viability for this group is 82.53 (±0.62; n = 12), while viability for the 70% PEG only group is 79.50 (±0.56; n = 11). Though these differences appear to be slight, they are statistically significant (p = 0.0008) and it is important to note that once these cells are plated immediately post-fusion, they receive no further supplementation or manipulation.
Similarly to the Rodriguez-Feo report, the current in vitro data shows that bzATP is deceiving. It appears to show some initial benefit in fusion, but as time progresses it leads to catastrophic decreases in viability providing no lasting measurable benefit. However, the lowest dose of bzATP, 5 mM, produced the best fusion and was no different than PEG alone in terms of viability, suggesting that with optimization very small doses of bzATP may augment PEG cell-fusion without greatly impacting viability. This new data highlights the importance of pre-clinical testing of chemical dosages and finding the balance between increasing and maintaining fusion while maintaining viability. Looking at the current data, bzATP is powerful even at very small doses so the effective dose range will be very narrow, while the data supports FCF having a broader effective dose range.
All PEG-treated samples demonstrated an overall decrease in fusion over time, which is most likely at least partially explained by the nature of our flow cytometry analysis, measuring fusion as a percentage of the whole sample. As cells proliferated over the 72-hour incubation period, during which PEG was absent, the overall proportion of fused cells as compared to the entire population necessarily decreased, although it is possible that the raw number of fused cell bodies did not. It is also likely that fusion was underreported using our methods, as the flow cytometer used in this manner does not identify dual green-green and violet-violet fusion events. Fusion is indiscriminate, so it can be assumed that green-green, violet-violet, and even multi-cell (for example, green-green-violet) fusion occurs with the same frequency as green-violet doublet fusion, suggesting an underrepresentation of fusion events in the absence of any cell sorting. This is encouraging for PEG fusion as a clinical treatment technique, as use of PEG in patients will most likely see functional results beyond what is predicted based on deflated in vitro results.
However, there are limitations to this type of experiment. Peripheral nerves are complex structures containing connective tissue, blood vessels, and many glial cell types, which influence and regulate cell behavior. For our experiment, we tested this procedure against previously published works examining p2x7 receptor modulation on sciatic nerve PEG-fusion. Modulation of the receptor was known to impact PEG fusion outcomes and was readily modulated in culture, using commercially available neuroblastoma cells. In order to study other receptors present on glia cells, it may be necessary to choose a different cell type. In short, this technique will not replace all in vivo work, but can inform on those experiments. The current in vitro model has supported previous reports and has provided some new information. Previously, it would have required very animal intensive and laborious experiments to arrive at appropriate dosages for powerful chemicals, such as bzATP. The development of this in vitro model will limit our need for animal testing only to chemicals that prove to augment PEG-mediated cell-fusion and/or viability. In this way, the in vitro PEG-mediated fusion model will be a valuable tool for assessing future proposed chemical modulators of PEG-mediated fusion. 
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